Linde Raises $1.7 Billion for U.S. Lincare Acquisition

German industrial gases producer Linde raised €1.4 billion ($1.7 billion) from a capital increase to help fund its $4.6 billion purchase of U.S. group Lincare.

The operator of air separation plants for steelmakers and supplier of medical gases said on Tuesday it was issuing 12.84 million new shares at €109 each.

The offer price came in at the bottom of a pricing range of €109.00-111.50 that two traders had provided to Reuters. Linde declined to comment on that range.

Linde said on Monday it would go ahead with a private placement that excluded both subscription rights and a public offer.

As part of Linde's planned acquisition of Lincare, which would make it the world's largest supplier of medical gases, Linde said last week it would increase its capital by up to €1.5 billion.

"The strategic fit is obvious," said Silvia Quandt research analysts Ralf Groenemeyer, reaffirming his buy rating and €130 price target.

"The Lincare acquisition would make the company's earnings less cyclical, actually commanding higher valuation multiples."

Steffen Manske, an analyst with Essen, Germany-based National Bank argued investors had punished the share enough for the sizeable acquisition: "We continue to believe the takeover plan makes sense and is attractive for Linde and regard share price declines of 4% at overdone."

 

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.